Serious vaccine risks accepted by FDA
Published: October 25, 2026
Duration: 19:47
Serious Adverse Events
Uploaded 02-06-25
https://www.fda.gov/media/186738/download?attachment
MNEXSPIKE group
Serious adverse events were reported by 2.7% of participants (n=156)
Comparator vaccine
Serious adverse events were reported by and 2.6% of participants (n=151)
(median follow-up of 8.8 months).
https://cardiovascular-research-and-innovation.reseaprojournals.com/archive_files/Myocarditis%20after%20SARS-CoV-2%20infection%20and%20COVID-19%20vaccination%20Epidemiology,%20outcomes,%20and%20new%20perspectives.pdf
https://investors.modernatx.com/news/news-details/2025/Moderna-Receives-U-S--FDA-Approval-for-COVID-19-Vaccine-mNEXSPIKE/default.aspx
https://www.fda.gov/vaccines-blood-biologics/mnexspike
Targeted approach...